https://pharminent.com/novo-nordisks-ziltivekimab-misses-primary-endpoint-in-pivotal-cardiovascular-trial/ 2026-08-01T01:28:46Z Pharminent en Novo Nordisk's Ziltivekimab Misses Primary Endpoint in Pivotal Cardiovascular Trial 2026-08-01T01:25:56Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-july-31-2026/ 2026-08-01T01:07:45Z Pharminent en Strategic News Watch • July 31, 2026 2026-08-01T01:07:43Z Blog https://pharminent.com/rare-disease-gene-therapy/rare-disease-gene-therapy-digest-july-30-2026/ 2026-07-30T22:11:13Z Pharminent en Rare Disease & Gene Therapy Digest • July 30, 2026 2026-07-30T22:11:11Z Blog https://pharminent.com/amgens-repatha-wins-positive-chmp-opinion-for-preventing-first-heart-attacks-and-strokes/ 2026-07-30T20:08:59Z Pharminent en Amgen's Repatha Wins Positive CHMP Opinion for Preventing First Heart Attacks and Strokes 2026-07-30T20:08:55Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-july-30-2026/ 2026-07-30T16:21:19Z Pharminent en Strategic News Watch • July 30, 2026 2026-07-30T16:21:16Z Blog https://pharminent.com/neuromarket-pulse/neuromarket-pulse-weekly-neuroscience-competitive-intelligence-july-29-2026/ 2026-07-30T14:49:42Z Pharminent en NeuroMarket Pulse • Weekly Neuroscience Competitive Intelligence • July 29, 2026 2026-07-30T14:49:40Z Blog